RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus

Key Takeaways RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.Rocket Pharmaceuticals (RCKT) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the com ...